nach oben

Medical Oncology

Erschienen in:

01.03.2008 | Original Paper

Liver embolizations in oncology: A review

Part I. Arterial (chemo)embolizations

verfasst von: Peter Gunvén

Erschienen in: Medical Oncology | Ausgabe 1/2008

Einloggen, um Zugang zu erhalten

Abstract

Arterial embolization of the liver often temporarily retards the growth of liver tumors which are mainly nourished arterially. The use of degradable agents avoids collateral formation which would prohibit repeat procedures and permit tumor regrowth. The effect of embolizations is largest in small hypervascular lesions, e.g., many hepatocellular or neuroendocrine cancers. Toxic chemicals can be added, chemoembolization, with unproven effects on responses and survival rates. Institutional differences in indications and procedures make evaluation of embolizations difficult. However, intermediate-term survival increases in selected cases of unresectable hepatocellular cancers and hormonal symptoms from neuroendocrine tumors often improve. Scant experience supports embolization for anti-tumoral effects in some pediatric tumors, to control bleeding from ruptured tumors, for symptomatic hemangiomas, and for downstaging of hepatocellular cancers before transplantation.

Wallace S, et al. Hepatic artery infusion and chemoembolization in the management of liver metastases. Cardiovasc Intervent Radiol 1990;13:153–60.PubMed

Belghiti J, et al. Continuous versus intermittent portal triad clamping for liver resection: a controlled study. Ann Surg 1999;229:369–75.PubMed

Hiatt JR, Gabbay J, Busuttil RW. Surgical anatomy of the hepatic arteries in 1000 cases. Ann Surg 1994;220:50–2.PubMed

Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol 1997;52:36–40.PubMed

Walser RH, et al. Diagnostic angioscintigraphic evaluation of malignant hepatic tumors before catheter embolization: determination of shunt, flow distribution, and reflux. Cardiovasc Intervent Radiol 1996;19:77–81.PubMed

Chung JW, Park JH, Im JG, Han JK, Han MC. Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1993;187:689–93.PubMed

Sakamoto I, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 1998;18:605–19.PubMed

Yoo KM, Yoo BG, Kim KS, Lee SU, Han BH. Cerebral lipiodol embolism during transcatheter arterial chemoembolization. Neurology 2004;63:181–3.PubMed

Huang MS, et al. Comparison of long-term effects between intra-arterially delivered ethanol and Gelfoam for the treatment of severe arterioportal shunt in patients with hepatocellular carcinoma. World J Gastroenterol 2004;10:825–9.PubMed

10.

Shimamura Y, Gunven P, Ishii M, Abe K. Temporary redistribution of hepatic or pancreatic blood flow by vascular occluders during intra-arterial chemotherapy for carcinoma of the liver or pancreas. Surg Gynecol Obstet 1993;177:617–9.PubMed

11.

Gates J, Hartnell GG, Stuart KE, Clouse ME. Chemoembolization of hepatic neoplasms: safety, complications, and when to worry. Radiographics 1999;19:399–414.PubMed

12.

Brown DB, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2006;17(2 Pt 1):225–32.PubMedCrossRef

13.

Shimamura Y, et al. Combined peripheral and central chemoembolization of liver tumors. Experience with lipiodol-doxorubicin and gelatin sponge (L-TAE). Cancer 1988;61:238–42.PubMed

14.

De Maio E, et al. Transcatheter arterial procedures in the treatment of patients with hepatocellular carcinoma: a review of literature. Crit Rev Oncol Hematol 2003;46:285–95.PubMed

15.

Llovet JM, et al. (Barcelona Liver Cancer Group). Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359(9319):1734–39.PubMed

16.

Pelletier G, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHCJ Hepatol 1998;29:129–34.

17.

Lo CM, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164–71.PubMed

18.

Madden MV, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:1598–600.PubMed

19.

Bruix J, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578–83.PubMed

20.

Latoo MY, Oliver A, Roebuck D. Anaesthetic management of hepatic artery chemoembolization in a paediatric patient. Paediatr Anaesth 2002;12:629–31.PubMed

21.

Park JW. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol 2005;100:2194–200.PubMed

22.

Jang JW. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology 2006 Feb;43(2):233–40.

23.

Chen MS, et al. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 2002;8:74–8.PubMed

24.

Cheng HY, et al. Adjustment of lipiodol dose according to tumor blood supply during transcatheter arterial chemoembolization for large hepatocellular carcinoma by multidetector helical CT. World J Gastroenterol 2004;10:2753–55.PubMed

25.

Raoul JL, et al. Chemoembolization of hepatocellular carcinomas. A study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992;70:585–90.PubMed

26.

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;47:479–47.

27.

Camma C, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47–54.PubMed

28.

Lu W, Li Y, He X, Chen Y. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kinds of dosages of anticancer drugs and analysis of prognostic factors. Hepatogastroenterology 2003;50:2079–83.PubMed

29.

Castells A, et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 1995;22:460–5.

30.

Kaibori M, et al. Preoperative chemolipiodolization of the whole liver for hepatocellular carcinoma. Anticancer Res 2004;24(3b):1929–33.PubMed

31.

Hatanaka Y, et al. Unresectable hepatocellular carcinoma: analysis of prognostic factors in transcatheter management. Radiology 1995;195:747–52.PubMed

32.

Lu CD, Qi YG, Peng SY. Lipiodolization with or without gelatin sponge in hepatic arterial chemoembolization for hepatocellular carcinoma. Chin Med J (Engl) 1994;107:209–15.

33.

Wigmore SJ, et al. Postchemoembolisation syndrome–tumour necrosis or hepatocyte injury? Br J Cancer 2003;89:1473–77.

34.

Song SY, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 2001;12:313–320.PubMed

35.

X-ray contrast media. Pharmacology, clinic. (Review in Swedish.) The Swedish Board of Health and Welfare, Drug Information 1976;3:1 p. 53–9 (Socialstyrelsens läkemedelsinformation. Röntgenkontrastmedel. Farmakologi, klinik. 1976 3:1, p. 53–59).

36.

Nakamura H, et al. Outcome of localized hepatocellular carcinoma treated with segmental arterioportal chemoembolization. Cancer Chemother Pharmacol 1992;31 Suppl:S69–S71.PubMed

37.

Huo TI, Wu JC, Lee PC, Chang FY, Lee SD. Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study. Liver Int 2004;24:210–5.PubMed

38.

Brown DB. Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. J Vasc Interv Radiol 2006;17(2 Pt 1):217–23.PubMed

39.

Ryu M, et al. Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Jpn J Clin Oncol 1997;27:251–7.PubMed

40.

Takayasu K, et al. Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. AJR Am J Roentgenol 2000;175:699–704.PubMed

41.

Yamasaki S, et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996;87:206–11.PubMed

42.

Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002;3:593–603.PubMed

43.

Chan ES, Chow PK, Tai B, Machin D, Soo K. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma. Cochrane Database Syst Rev 2000;(2):CD001199.

44.

Wu CC, et al. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995;82:122–6.PubMed

45.

Bhattacharya S, et al. Small hepatocellular carcinomas in cirrhotic explant livers: identification by macroscopic examination and lipiodol localization. Hepatology 1997;25:613–8.PubMed

46.

Kwok PC, et al. Randomized controlled trial to compare the dose of adjuvant chemotherapy after curative resection of hepatocellular carcinoma. J Gastroenterol Hepatol 2003;18:450–5.PubMed

47.

Shimamura Y, Gunven P, Ishii M, Ono M, Abe K. Debulking surgery and arterial embolization for unresectable liver cancer. Hepatogastroenterology 1993;40:10–3.PubMed

48.

Inoue K, et al. Volume reduction surgery for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:362–6. Epub 2004 Mar 18.PubMed

49.

Wakabayashi H, et al. Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions. J Surg Oncol 2003;82:98–103.PubMed

50.

Takayasu K, et al. Clinical and radiologic assessments of the results of hepatectomy for small hepatocellular carcinoma and therapeutic arterial embolization for postoperative recurrence. Cancer 1989;64:1848–52.PubMed

51.

Okazaki M, et al. Chemoembolotherapy for recurrent hepatocellular carcinoma in the residual liver after hepatectomy. Hepatogastroenterology 1993;40:320–3.PubMed

52.

Bartolozzi C, et al. Treatment of large HCC: transcatheter arterial chemoembolization combined with percutaneous ethanol injection versus repeated transcatheter arterial chemoembolization. Radiology 1995;197:812–8.PubMed

53.

Koda M, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma: a randomized control study. Cancer 2001;92:1516–24.PubMed

54.

Kamada K, et al. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma. Am J Surg 2002;184:284–90.PubMed

55.

Dohmen K, et al. Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate. Hepatogastroenterology 2001;48:1409–65.PubMed

56.

Tanaka K, et al. The long term efficacy of combined transcatheter arterial embolization and percutaneous ethanol injection in the treatment of patients with large hepatocellular carcinoma and cirrhosis. Cancer 1998;82:78–85.PubMed

57.

Lencioni R, et al. Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and long-term survival rate. Eur Radiol 1998;8:439–44.PubMed

58.

Akamatsu M, et al. Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial. Liver Int 2004;24:625–9.PubMed

59.

Marelli L. Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev 2006;32:594–606.PubMed

60.

Yeung YP, et al. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol 2005;100:1995–2004.PubMed

61.

Arai K, et al. Efficacy of transcatheter arterial embolization therapy for small hepatocellular carcinomas: comparison with other treatments. Radiat Med 1990;8:191–8.PubMed

62.

Jang MK, et al. Role of additional angiography and chemoembolization in patients with hepatocellular carcinoma who achieved complete necrosis following transarterial chemoembolization. J Gastroenterol Hepatol 2004;19:1074–80.PubMed

63.

Brown DB, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004;15:1209–18.PubMedCrossRef

64.

O’Suilleabhain CB, et al. Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma. Br J Surg 2003;90:325–31.PubMed

65.

Pelletier G, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181–4.PubMed

66.

Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma -a randomized controlled trial. Gastroenterology 1988 ;94:453–6.PubMed

67.

Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256–61.

68.

Geschwind JF, Ramsey DE, Choti MA, Thuluvath PJ, Huncharek MS. Chemoembolization of hepatocellular carcinoma: results of a metaanalysis. Am J Clin Oncol 2003;26:344–9.PubMed

69.

Reidy DL, Schwartz JD. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials – I: hepatic arterial embolization and embolization-based therapies in unresectable hepatocellular carcinoma. Anticancer Drugs 2004;15:427–37.PubMed

70.

Staunton M, Dodd JD, McCormick PA, Malone DE. Finding evidence-based answers to practical questions in radiology: which patients with inoperable hepatocellular carcinoma will survive longer after transarterial chemoembolization? Radiology 2005;237:404–13.PubMed

71.

Llovet JM, Sala M. Non-surgical therapies of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17:505–13.PubMed

72.

Lee HS, et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002;20:4459–65.PubMed

73.

Mok KT, et al. Multimodality management of hepatocellular carcinoma larger than 10 cm. J Am Coll Surg 2003;197:730–8.PubMed

74.

Liem MS, Poon RT, Lo CM, Tso WK, Fan ST. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J Gastroenterol 2005;11:4465–71.PubMed

75.

Wall WJ, Marotta PJ. Surgery and transplantation for hepatocellular cancer. Liver Transpl 2000;6(6 Suppl 2):S16–22.PubMed

76.

Decaens T, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005;11:767–75.PubMed

77.

Fisher RA, et al. Non-resective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004;18:502–12.PubMed

78.

Herber S, et al. TACE: therapy of the HCC before liver transplantation—experiences. (in German) Rofo 2005;177:681–90.PubMed

79.

Cheng YF, et al. Impact of pre-operative transarterial embolization on the treatment of hepatocellular carcinoma with liver transplantation. World J Gastroenterol 2005;11:1433–38.PubMed

80.

Roche A, et al. Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 2003;13:136–40. Epub 2002 Jul 23.PubMed

81.

Zimmer C, Kienbaum P, Wiesemes R, Peters J. Somatostatin does not prevent serotonin release and flushing during chemoembolization of carcinoid liver metastases. Anesthesiology 2003;98:1007–11.PubMed

82.

Ahlman H, Nilsson O, Olausson M. Interventional treatment of the carcinoid syndrome. Neuroendocrinology 2004;80(Suppl 1):67–73.PubMed

83.

Gupta S, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005;104:1590–1602.PubMed

84.

Venook AP. Embolization and chemoembolization therapy for neuroendocrine tumors. Curr Opin Oncol 1999;11:38–41.PubMed

85.

O’Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol 2005;19:585–94.PubMed

86.

Kulke M. Advances in the treatment of neuroendocrine tumors. Curr Treat Options Oncol 2005;6:397–409.PubMed

87.

Touzios JG, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005;241:776–83.PubMed

88.

Meij V, et al. Local treatment in unresectable hepatic metastases of carcinoid tumors: Experiences with hepatic artery embolization and radiofrequency ablation. World J Surg Oncol 2005;3:75.PubMed

89.

Moertel CG, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 1994;120:302–9.PubMed

90.

Hirshberg B, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer 2005;104:264–72.PubMed

91.

Nesovic M, Ciric J, Radojkovic S, Zarkovic M, Durovic M. Improvement of metastatic endocrine tumors of the pancreas by hepatic artery chemoembolization. J Endocrinol Invest 1992;15:543–7.PubMed

92.

Starke A, et al. Malignant metastatic insulinoma-postoperative treatment and follow-up. World J Surg 2005;29:789–93.PubMed

93.

Scott A, Hinwood D, Donnelly R. Radio-frequency ablation for symptom control in a patient with metastatic pancreatic insulinoma. Clin Endocrinol 2002;56:557–9.

94.

Civera Andres M, Real Collado JT, Martinez Uso I, Ampudia Blasco FJ, Carmena Rodriguez R. Selective therapeutic embolization in malignant insulinoma (in Spanish). Rev Clin Esp 2000;200:548–50.PubMed

95.

Sato T, et al. Strategy for pancreatic endocrine tumors. Hepatogastroenterology 2000;47:537–9.PubMed

96.

Roche A, et al. Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepatogastroenterology 2004;51:1751–6.PubMed

97.

Brentjens R, Saltz L. Islet cell tumors of the pancreas: the medical oncologist’s perspective. Surg Clin North Am 2001;81:527–42.PubMed

98.

Neuroendocrine tumors. National Comprehensive Cancer Network: Clinical practice guidelines in oncology version 2.2005. hhtp://www.nccn.org/professionals/physician-gls/PDF/neuroendocrine.pdf

99.

Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am 2001;81:511–25.PubMed

100.

Plöckinger U, et al. European Neuroendocrine Tumour Society. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394–424. Epub 2005 Apr 18.PubMed

101.

Hage R, de la Riviere AB, Seldenrijk CA, van den Bosch JM. Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol 2003;10:697–704.PubMed

102.

Chamberlain RS, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190:432–45.PubMed

103.

Lorenz K, et al. Selective arterial chemoembolization for hepatic metastases from medullary thyroid carcinoma. Surgery 2005;138:986–93.PubMed

104.

Ohtsuka Y, et al. Optimal strategy of preoperative transcatheter arterial chemoembolization for hepatoblastoma. Surg Today 2004;34:127–33.PubMed

105.

Warmann S, et al. Interventional treatment of infantile hepatic hemangioendothelioma. J Pediatr Surg 2003;38:1177–81.PubMed

106.

Malogolowkin MH, Stanley P, Steele DA, Ortega JA. Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 2000;18:1279–84.PubMed

107.

Arcement CM, et al. Intrahepatic chemoembolization in unresectable pediatric liver malignancies. Pediatr Radiol 2000;30:779–85.PubMed

108.

Lee SC, Chung JW, Kim KH, Kim WK. Successful transumbilical embolization of congenitally ruptured hepatoblastoma. J Pediatr Surg 1999;34:1851–52.PubMed

109.

Weintraub M, et al. Successful treatment of progressive stage 4s hepatic neuroblastoma in a neonate with intra-arterial chemoembolization. Pediatr Blood Cancer 2004;43:148–51.PubMed

110.

Yokoi Y, et al. Aggressive hepatectomy for complete remission of metastatic germ cell tumor following chemotherapy: report of a case. Hepatogastroenterology 2003;50:1136–9.PubMed

111.

St Peter SD, Moss AA, Huettl EA, Leslie KO, Mulligan DC. Chemoembolization followed by orthotopic liver transplant for epithelioid hemangioendothelioma. Clin Transplant 2003;17:549–53.PubMed

112.

Lang EK, Brown CL Jr. Colorectal metastases to the liver: selective chemoembolization. Radiology 1993;189:417–22.PubMed

113.

Martinelli DJ, et al. Utility of embolization or chemoembolization as second-line treatment in patients with advanced or recurrent colorectal carcinoma. Cancer 1994;74:1706–12.PubMed

114.

Salman HS, et al. Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2002;2:173–9.PubMedCrossRef

115.

Kameyama M, et al. Delayed washout of intratumor blood flow is associated with good response to intraarterial chemoembolization for liver metastasis of colorectal cancer. Surgery 1993;114:97–101.PubMed

116.

Hunt TM, et al. Prospective randomized controlled trial of hepatic arterial embolization or infusion chemotherapy with 5-fluorouracil and degradable starch microspheres for colorectal liver metastases. Br J Surg 1990;77:779–82.PubMed

117.

Burger I, et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005;16:353–61.PubMed

118.

Rajan DK, et al. Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 2001;12:187–93.PubMed

119.

Kobayashi K, et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer 2006;107:2833–41.PubMed

120.

Feldman ED, Pingpank JF, Alexander HR Jr. Regional treatment options for patients with ocular melanoma metastatic to the liver. Ann Surg Oncol 2004;11:290–97.PubMed

121.

Bedikian AY, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer 1995;76:1665–70.PubMed

122.

Agarwala SS, Panikkar R, Kirkwood JM. Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res 2004;14:217–22.PubMed

123.

Giroux MF, Baum RA, Soulen MC. Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 2004;15:289–91.PubMed

124.

Li XP, Meng ZQ, Guo WJ, Li J. Treatment for liver metastases from breast cancer: results and prognostic factors. World J Gastroenterol 2005;11:3782–7.PubMed

125.

Braga L, et al. Does hypervascularity of liver metastases as detected on MRI predict disease progression in breast cancer patients? AJR Am J Roentgenol 2004;182:1207–13.PubMed

Titel: Liver embolizations in oncology: A review
Part I. Arterial (chemo)embolizations
verfasst von: Peter Gunvén
Publikationsdatum: 01.03.2008
Verlag: Humana Press Inc
Erschienen in: Medical Oncology / Ausgabe 1/2008
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-007-0039-3

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Liver embolizations in oncology: A review

Part I. Arterial (chemo)embolizations

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2008

Bleomycin, etoposide and cisplatin (BEP) combination with concurrent imatinib mesylate (GLEEVEC) in chronic myeloid leukemia (CML) patient with mesenchymal tumor

Functional characterization of the GDEP promoter and three enhancer elements in retinoblastoma and prostate cell lines

Clinical characteristics and outcome of patients with stage III esophageal carcinoma: a single-center experience from Turkey

Renal cell carcinoma presenting as a huge simple renal cyst

Survival and erythropoietin receptor protein in tumours from patients randomly treated with rhEPO for palliative care

Thiopurine S-methyltransferase Gene (TMPT) polymorphisms in a Mexican population of healthy individuals and leukemic patients

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie